Sign Up to like & get
recommendations!
0
Published in 2018 at "Oncology"
DOI: 10.1159/000486624
Abstract: Background: Regorafenib is an oral multikinase inhibitor with a proven survival benefit for metastatic colorectal cancer patients. The KSCC1402/HGCSG1402 study investigated the prophylactic effect of oral dexamethasone (DEX) on regorafenib-related fatigue and/or malaise. Patients and…
read more here.
Keywords:
fatigue malaise;
group;
regorafenib related;
related fatigue ... See more keywords